Marker Therapeutics (MRKR) Shares Outstanding (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Shares Outstanding (Entity) of $16.7 million for Q1 2026, up 49.11% year-over-year from $11.2 million in Q1 2025, and little changed quarter-over-quarter from $16.7 million in Q4 2025.
Marker Therapeutics (MRKR) Shares Outstanding (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Shares Outstanding (Entity) for 17 consecutive years, with $16.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 49.11% year-over-year to $16.7 million; the TTM figure through Mar 2026 stood at $16.7 million (up 49.11% YoY), while the FY2025 annual figure was $16.7 million, up 56.07% from the prior year.
- Shares Outstanding (Entity) was little changed at $16.7 million in Q1 2026 per MRKR's latest filing, from $16.7 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $16.7 million in Q3 2025 and bottomed at $8.4 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $10.5 million across 5 years, with a median of $8.9 million in 2023.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) advanced 0.6% — and 2025, when it jumped 87.64%.
- Marker Therapeutics' Shares Outstanding (Entity) stood at $8.4 million in 2022, then rose by 5.95% to $8.9 million in 2023, then climbed by 20.22% to $10.7 million in 2024, then jumped by 56.07% to $16.7 million in 2025, then changed by 0.0% to $16.7 million in 2026.
- Business Quant data shows MRKR's Shares Outstanding (Entity) at $16.7 million in Q1 2026, $16.7 million in Q4 2025, and $16.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | 19.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.31 Mn |
| Dec 31, 2025 | 15.31 Mn |
| Sep 30, 2025 | 16.76 Mn |
| Jun 30, 2025 | 13.96 Mn |
| Mar 31, 2025 | 11.11 Mn |
| Dec 31, 2024 | 8.98 Mn |
| Sep 30, 2024 | 8.92 Mn |
| Jun 30, 2024 | 8.92 Mn |
| Mar 31, 2024 | 8.90 Mn |
| Dec 31, 2023 | 8.81 Mn |
| Sep 30, 2023 | 8.83 Mn |
| Jun 30, 2023 | 8.80 Mn |
| Mar 31, 2023 | 8.72 Mn |
| Dec 31, 2022 | 8.35 Mn |
| Sep 30, 2022 | 8.36 Mn |
| Jun 30, 2022 | 8.36 Mn |
| Mar 31, 2022 | 8.31 Mn |
| Dec 31, 2021 | 7.65 Mn |
| Sep 30, 2021 | 8.31 Mn |
| Jun 30, 2021 | 8.30 Mn |